Open Access
Med Sci (Paris)
Volume 38, Number 1, Janvier 2022
Page(s) 21 - 22
Section Le Magazine
Published online 21 January 2022
  1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010 ; 362 : 2380–2388. [CrossRef] [PubMed] [Google Scholar]
  2. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018 ; 378 : 731–739. [CrossRef] [PubMed] [Google Scholar]
  3. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1–2 trials. Lancet Oncol 2020; 21 : 271–82. [CrossRef] [PubMed] [Google Scholar]
  4. du Rusquec P, Le Tourneau C. Drug development in tissue-agnostic indications. Cancers (Basel) 2021; 13 : 2758. [CrossRef] [PubMed] [Google Scholar]
  5. Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res 2019 ; 47 : D941–D947. [CrossRef] [PubMed] [Google Scholar]
  6. ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 2020; 578 : 82–93. [CrossRef] [PubMed] [Google Scholar]
  7. Westphalen CB, Krebs MG, Le Tourneau C, et al. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol 2021; 5 : 69. [CrossRef] [PubMed] [Google Scholar]
  8. Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 2018 ; 29 : 1895–1902. [CrossRef] [PubMed] [Google Scholar]
  9. Petak I, Kamal M, Dirner A, et al. A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial. NPJ Precis Oncol 2021; 5 : 59. [CrossRef] [PubMed] [Google Scholar]
  10. Le Tourneau C, Delord JP, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015 ; 16 : 1324–1334. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.